Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Common Equity (2024 - 2025)

BioAge Labs (BIOA) has disclosed Common Equity for 2 consecutive years, with $272.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 15.81% to $272.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $272.1 million through Dec 2025, down 15.81% year-over-year, with the annual reading at $272.1 million for FY2025, 15.81% down from the prior year.
  • Common Equity hit $272.1 million in Q4 2025 for BioAge Labs, down from $277.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $323.1 million in Q4 2024 to a low of -$197.1 million in Q2 2024.